

Intra-Vitreous Injections or Implants

Reference Number: RDF1510-23

Date of Response: 18/07/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon and Exeter NHS Foundation Trust,

I am analysing the usage of intra-vitreous injections or implants by the NHS. Could you please tell me how many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2023:

Answer: Please see table below.

Name	Administered
Aflibercept	3438
Bevacizumab	Nil
Brolucizumab	≤5
Dexamethasone	Nil
Faricimab	108
Fluocinolone acetonide	Nil
Ranibizumab - Lucentis	279
Ranibizumab – Ongavia	20
Ranibizumab – Byooviz	Nil
Ranibizumab - Ximluci	Nil

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.